CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges to provide these agents at concentrations necessary to extinguish cell cycling in tumors. HR+ breast cancer cells are highly dependent on CDK4 but not CDK6. By contrast, CDK4 is dispensable for human bone marrow derived cells, due to the primary and compensatory role of CDK6 in hematopoiesis. This prompted us to develop atirmociclib (PF-07220060), a next-generation CDK4 selective inhibitor. Atirmociclib's impact on circulating neutrophils was reduced, in proportion with its increase in CDK4 versus CDK6 selectivity. Realized dose intensification led to greater CDK4 inhibition and deeper anti-tumor responses, pointing to CDK4 target coverage as a limiting factor of CDK4/6 inhibitor efficacy. We also highlight combinatorial agents that may counter acquired resistance to CDK4 selective inhibition and widen its clinical application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccell.2025.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Schisandrin B targets CDK4/6 to suppress proliferation and enhance radiosensitivity in nasopharyngeal carcinoma by inducing cell cycle arrest.
Sci Rep
March 2025
The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, No.6 Jiefang Street, Zhongshan District, Dalian, 116001, Liaoning, China.
Nasopharyngeal carcinoma (NPC) is notably prevalent in East and Southeast Asia, where despite advancements in radiotherapy leading to high control rates, challenges like radioresistance and collateral tissue damage remain significant. While Schisandrin B (SchB) has been demonstrated antitumor effects in various tumors, its efficacy in NPC remains unexplored. In this study, we explored the antitumor potential of Sch B on NPC, particularly its effects on cell proliferation and radiosensitivity.
View Article and Find Full Text PDFCDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.
Cancer Cell
March 2025
Pfizer Global Research and Development La Jolla, 10770 Science Center Drive, San Diego, CA 92121, USA. Electronic address:
CDK4/6 inhibitors have revolutionized treatment of hormone receptor positive (HR+), HER2 non-amplified (HER2-) breast cancer. Yet, all "dual" CDK4/6 inhibitors show common dose-limiting hematologic toxicities, foremost neutropenia. This poses challenges to provide these agents at concentrations necessary to extinguish cell cycling in tumors.
View Article and Find Full Text PDFA CDK4-selective inhibitor puts the brakes on cancer cells.
Cancer Cell
March 2025
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Electronic address:
In this issue of Cancer Cell, Palmer et al. describe the discovery and preclinical testing of the first-in-class CDK4-selective inhibitor atirmociclib. By sparing CDK6, atirmociclib has the potential to ameliorate dose-limiting hematological toxicities that limit drug exposure and treatment continuity and, by extension, the antitumor efficacy of dual CDK4/6 inhibitors.
View Article and Find Full Text PDFDevelopment of 9H-purine scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation.
Bioorg Med Chem Lett
March 2025
School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, PR China. Electronic address:
Cyclin-dependent kinase 2 (CDK2), a crucial regulator in multiple oncogenic signaling pathways, has emerged as a promising target for the development of innovative anticancer therapies and overcoming resistance to CDK4/6 inhibitors. In this study, three series of compounds were designed and synthesized, using the CDK2 inhibitor fadraciclib (CYC065) as the lead compound, with 9H-purine as the core structure. The design incorporated reported structure-activity relationship data and utilized computer-aided drug design techniques.
View Article and Find Full Text PDFMolecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.
Discov Oncol
March 2025
Department of Clinical and Administrative Pharmacy Sciences, Howard University, 2400 Sixth Street NW, Washington, DC, 20059, USA.
Background: Colorectal cancer (CRC) is the second most common cancer in men and third in females, a heterogeneous disease involving multistep mechanisms that represents 10% of all cancers globally. This study investigates gene mutation profiling in CRC using Next-Generation sequencing machine.
Method: Formalin-fixed paraffin-embedded tissues of 30 CRC patients were retrieved and reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!